Viking Therapeutics acquisition odds have fallen hard since early July, and the two venues carrying the contract now agree with each other. This binary market asks whether any buyer agrees to acquire the obesity-drug developer before 2027, and it trades across roughly $1.7M in cumulative volume on Kalshi and Polymarket. The live board above shows both venues. The market resolves December 31, 2026.
Viking Therapeutics is still the obesity trade's most-discussed takeover name, and the market that prices it has moved decisively. The contract asks one clean question: will any entity agree to acquire Viking Therapeutics before 2027? It carries roughly $1.7M in cumulative cross-platform volume and resolves December 31, 2026. Two things have changed since early July. The implied probability has fallen by more than half, and the two venues carrying the contract, which spent months disagreeing, have closed almost the entire gap between them.
Viking's appeal to acquirers starts with one asset: VK2735, a wholly owned dual agonist of the GLP-1 and GIP receptors aimed at obesity. Viking controls both an injectable and an oral version of the same molecule, which is rare among the late-stage obesity developers still trading independently. Both Phase 3 VANQUISH studies of the injectable are fully enrolled and proceeding to plan, VANQUISH-1 with roughly 4,500 adults with obesity or overweight and VANQUISH-2 with roughly 1,000 adults who also have type 2 diabetes. Viking expects to complete those studies in 2027. The oral VK2735 Phase 3 program is scheduled to begin in the fourth quarter of 2026, and a Phase 1 single ascending dose trial of the amylin agonist VK3019 started in the second quarter.
The balance sheet has thinned. Viking reported second-quarter results on July 29, 2026, ending the quarter with $502M in cash, cash equivalents and short-term investments, down from $706M at the end of 2025. The company posted a $128.0M net loss in the quarter, or $1.10 per share, and $286.3M through six months against $265.9M of research and development spend. That is still not a forced-seller balance sheet. It is a smaller cushion than the one this page described in the spring, and the burn rate is the reason the runway question keeps coming up.
The structural problem for a Yes resolution is the calendar, not the thesis. The event that would most plausibly trigger a bid, pivotal Phase 3 VANQUISH data on the injectable, does not arrive until 2027, after this contract has already settled. An acquirer that wants Viking with the readout in hand has every reason to wait past December 31, 2026, and one that moves before the data pays for optionality it is not yet forced to pay for. Pfizer's win over Novo Nordisk for Metsera proved the majors will pay up for late-stage obesity assets. It did not prove they will pay up on this deadline.
The equity has not confirmed a deal is coming either. Shares traded near $33.49 on August 17, 2026, inside a 52-week range of $22.96 to $43.15, for a market cap around $3.91B. Sell-side conviction is still high but has been trimmed: JPMorgan cut its price target to $65 from $75 on August 11, 2026, and Cantor Fitzgerald reaffirmed a buy rating in mid-August. A stock trading near half the lowest of those targets is one the street thinks is cheap, not one trading on live deal terms.
The most useful change on this board is not the level, it is the agreement. Through the early summer, Kalshi and Polymarket carried materially different views of a Viking Therapeutics acquisition, with Polymarket traders near a coin flip while Kalshi traders leaned toward no deal. That gap has closed to a couple of cents. The live board above carries the current price on each venue.
Convergence is a real signal on a binary corporate event. When two independent order books with separate rulebooks, separate user bases and separate settlement language land on the same number, the disagreement that used to be the story on this market is gone. What replaces it is a shared read: the deadline is close, no acquisition agreement has been announced, and neither book prices one as the base case. The gap was never a free trade in either direction. The two contracts settle under different rulebooks and the Kalshi leg frequently posts zero 24-hour volume, so the spread was always a difference of opinion between thin books rather than something a trader could costlessly close.
The Viking Therapeutics acquisition market resolves December 31, 2026, at 11:59 PM ET. It settles Yes if credible reporting confirms that any entity enters into an agreement to acquire Viking by that deadline. An announced agreement counts for a Yes regardless of whether the deal ultimately closes, and a merger in which Viking is subsumed by another entity also counts. The primary resolution source is official information from Viking and its leadership, with a consensus of credible reporting used as a backstop. A signed agreement is the trigger, not a completed transaction, so a late-December announcement would resolve the market even if the closing runs into 2027.
Corporate buyout contracts trade as a family on the same December 31, 2026 deadline, and Viking is one of the more heavily traded names in it. The Nebius Group acquisition odds carry the largest book in the group at roughly $8.0M, while the GitLab acquisition market and the BP acquisition odds price takeover speculation in software and energy against the same clock. The Perplexity AI acquisition market covers the private-company side of the same question. For the wider category, browse finance prediction markets.
The Viking Therapeutics acquisition market resolves on December 31, 2026, at 11:59 PM ET. It settles Yes if credible reporting confirms that any entity enters into an agreement to acquire Viking Therapeutics by that deadline, and No otherwise. An announced acquisition agreement qualifies for a Yes resolution regardless of whether the transaction ultimately closes, and a merger in which Viking is subsumed by another company also counts as a Yes. The primary resolution source is official information from Viking Therapeutics and its leadership, supplemented by a consensus of credible reporting. Because the trigger is a signed agreement rather than a completed deal, a late-December 2026 announcement would resolve the market even if the closing extends into 2027.
As of August 17, 2026, a Viking Therapeutics acquisition before 2027 blends to 19c across platforms, with Kalshi at 18c and Polymarket at 20c. That is down from roughly 44c blended in early July, and the No side trades near 81c.
It resolves December 31, 2026, at 11:59 PM ET, settling Yes if any entity announces an agreement to acquire Viking by that deadline, regardless of whether the deal later closes.
The contract trades on both Kalshi and Polymarket, and the two order books now price it within a couple of cents of each other. Polymarket carries the more active book, while the Kalshi leg frequently posts zero 24-hour volume.
No acquisition agreement had been announced as of August 17, 2026, and pivotal Phase 3 VANQUISH data on injectable VK2735 is not expected until 2027, after this contract settles on December 31, 2026. That gives an acquirer a reason to wait rather than bid before the deadline.
Watch the Phase 1 VK2735 maintenance dosing results Viking expects in the third quarter of 2026, the oral VK2735 Phase 3 start scheduled for the fourth quarter, and any competing Big Pharma bid for an independent obesity developer before the December 31, 2026 deadline.